CASSAVA SCIENCES INC (SAVA) Fundamental Analysis & Valuation
NASDAQ:SAVA • US14817C1071
Current stock price
2.38 USD
+0.26 (+12.26%)
At close:
2.34 USD
-0.04 (-1.68%)
After Hours:
This SAVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SAVA Profitability Analysis
1.1 Basic Checks
- SAVA had negative earnings in the past year.
- SAVA had a negative operating cash flow in the past year.
- SAVA had negative earnings in each of the past 5 years.
- In the past 5 years SAVA always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of SAVA (-81.73%) is worse than 73.06% of its industry peers.
- SAVA has a worse Return On Equity (-129.99%) than 65.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.73% | ||
| ROE | -129.99% | ||
| ROIC | N/A |
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for SAVA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. SAVA Health Analysis
2.1 Basic Checks
- Compared to 1 year ago, SAVA has more shares outstanding
- SAVA has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for SAVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- SAVA has an Altman-Z score of -6.05. This is a bad value and indicates that SAVA is not financially healthy and even has some risk of bankruptcy.
- SAVA has a worse Altman-Z score (-6.05) than 63.73% of its industry peers.
- SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.05 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- SAVA has a Current Ratio of 2.27. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
- SAVA has a Current ratio (2.27) which is comparable to the rest of the industry.
- SAVA has a Quick Ratio of 2.27. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.27, SAVA perfoms like the industry average, outperforming 50.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.27 |
3. SAVA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 37.50% over the past year.
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- SAVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 102.72% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-35.77%
EPS Next 2Y6.85%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. SAVA Valuation Analysis
4.1 Price/Earnings Ratio
- SAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year SAVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SAVA's earnings are expected to grow with 102.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y102.72%
5. SAVA Dividend Analysis
5.1 Amount
- No dividends for SAVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SAVA Fundamentals: All Metrics, Ratios and Statistics
2.38
+0.26 (+12.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03 2026-03-03/amc
Earnings (Next)05-06 2026-05-06
Inst OwnersN/A
Inst Owner Change-0.08%
Ins OwnersN/A
Ins Owner Change1.23%
Market Cap114.98M
Revenue(TTM)N/A
Net Income(TTM)-106.03M
Analysts82.86
Price Target5.1 (114.29%)
Short Float %16.05%
Short Ratio9.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.41 | ||
| P/tB | 1.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS1.69
TBVpS1.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.73% | ||
| ROE | -129.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 16.53% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.27 | ||
| Altman-Z | -6.05 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.07%
EPS Next Y-35.77%
EPS Next 2Y6.85%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.42%
OCF growth 3YN/A
OCF growth 5YN/A
CASSAVA SCIENCES INC / SAVA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CASSAVA SCIENCES INC (SAVA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to SAVA.
What is the valuation status of CASSAVA SCIENCES INC (SAVA) stock?
ChartMill assigns a valuation rating of 1 / 10 to CASSAVA SCIENCES INC (SAVA). This can be considered as Overvalued.
What is the profitability of SAVA stock?
CASSAVA SCIENCES INC (SAVA) has a profitability rating of 0 / 10.
What is the earnings growth outlook for CASSAVA SCIENCES INC?
The Earnings per Share (EPS) of CASSAVA SCIENCES INC (SAVA) is expected to decline by -35.77% in the next year.